A recent systematic review of randomized controlled trials on the use of GLP-1 agonists for weight loss among adults without diabetes showed that, compared to placebo, tirzepatide (15 mg weekly) led to up to 17.8% weight loss after 72 weeks, SMG (2.4 mg weekly) up to 13.9% after 68 weeks, and liraglutide (3.0 mg daily) up to 5.8% after 26 weeks. Here, GLP1R is linked to diabetes mellitus.